Han Myint, M.D. | Chief Medical Officer
|Dr. Myint has over 20 years of experience in both academia and the biopharma industry. Before joining NextCure, he was chief medical officer at NexImmune, a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies. Prior to NexImmune, he was Vice President of Global Medical Affairs and the Myeloid Diseases Lead at Celgene. His work in myeloid diseases at Celgene contributed to a number of FDA approvals, successful launches of those products and high-impact publications. Prior to joining the biopharma industry, Dr. Myint practiced medicine specializing in hematological oncology and conducted clinical and laboratory research at multiple prestigious academic institutions in the UK and USA including Rush University Medical Center in Chicago and University of Colorado, Denver. Dr. Myint, Professor of Medicine, built a FACT-accredited and Center of Excellence-Designated Stem Cell Transplant Program at the University of Colorado, Denver. He has in-depth scientific knowledge, a wealth of clinical experience and expertise in hematological malignancies and stem cell transplantation. Dr. Myint graduated from the Institute of Medicine in Yangon with a MBBS degree and subsequently emigrated to the UK to do his postgraduate training in Internal Medicine, followed by his training in Hematology. Accordingly, he was awarded as a fellow from the Royal Colleges of Physicians and Pathologists from the UK and also from the American College of Physicians.||• Michael Richman
President & CEO
• Timothy Mayer, Ph.D.
• Steven P. Cobourn, CPA
• Han Myint, M.D.
• Sol Langermann, Ph.D.
• Linda Liu, Ph.D.
Senior Vice President, Research
• Sebastien Maloveste, Ph.D.
Vice President, Business Development
• Dallas Flies, Ph.D.
Vice President, Discovery Research
• Zachary Cusumano
Vice President, Project Management and Strategy